•   
  •   
  •   

Politics White House warns states to expect low weekly J&J vaccine shipments

20:55  09 april  2021
20:55  09 april  2021 Source:   thehill.com

Here's who's eligible for COVID-19 vaccines in each state

  Here's who's eligible for COVID-19 vaccines in each state The availability of COVID-19 vaccines is becoming more widespread, prompting states to increase the categories of residents eligible to get vaccinated.President Biden has directed states to make all adults eligible for a vaccine by May 1. More recently, he said he expects 90 percent of adults to be eligible for the vaccine by April 19.Every state has opened eligibility to residents age 65 or older, certain essential workers and residents 16 or older with certain high-risk medical conditions.Here's where each state and the District of Columbia stands on vaccine eligibility for other residents.AlabamaGov.

White House officials said Friday that states will receive substantially fewer doses of Johnson & Johnson's vaccine over the coming weeks, until the Food and Drug Administration can authorize the company's production facility in Baltimore.

text, letter: Johnson & Johnson coronavirus vaccine © Getty Images Johnson & Johnson coronavirus vaccine

"We expect a relatively low level of weekly doses distributed to states, tribes, territories and our federal channels" until the manufacturing facility is authorized, Jeff Zients, White House coronavirus response coordinator, said Friday.

Statistics from the Centers for Disease Control and Prevention indicate that Johnson & Johnson doses sent out will drop from about 4.9 million this week to 700,000 next week, a cut of 85 percent.

How the Novavax Covid-19 vaccine works

  How the Novavax Covid-19 vaccine works At the headquarters of biotechnology company Novavax, scientists are developing what they hope could soon be another Covid-19 vaccine for the United States.Data from the company's large-scale Phase 3 clinical trial of the vaccine in the US and Mexico are expected this month, but the timeline depends on how quickly it accumulates data on the prevalence of disease in trial areas.

The production boost this week was largely due to the FDA allowing contract manufacturer Catalent, which operates a "fill-finish" facility in Indiana, to ship millions of doses of the vaccine that had already been packaged and inspected.

Zients said officials expect a "messy fluctuation," and that he wouldn't speculate on timing of the Baltimore plant's authorization. He said Johnson & Johnson is working closely with the FDA to resolve manufacturing issues at the plant, which had been run by Emergent BioSolutions.

Zients said J&J has completely taken control of the facility, and has installed a new senior leadership team, after a quality control error at the plant resulted in the loss of 15 million doses.

Once Emergent gets FDA authorization, Zients said that the company expects a cadence of up to eight million weekly doses in total across state and federal channels later this month.

The company previously said it expects to deliver 24 million doses by the end of April, but it's not clear if that can happen without the Baltimore plant's authorization.

Zients said the company has pledged to provide "at or near" 100 million vaccine doses by the end of May.

America is about to hit a 'vaccine wall' as demand drops — with or without Johnson & Johnson .
When U.S. officials temporarily paused the use of Johnson & Johnson’s COVID-19 vaccine Tuesday to warn patients and providers of an “extremely rare” blood clotting issue that has so far affected just six of the millions of Americans who have received the vaccine — all six of them women ages 18 to 48 — many observers worried the abrupt move would stop a substantial number of Americans from getting vaccinated. Because even before the J&J news, theBut if you take a closer look at the data, it’s clear that unless regulators end up pulling J&J from the market — an outcome experts have all but ruled out, given the vaccine’s robust track record of safety and effectiveness and the relatively minuscule risk of clotting — th

usr: 1
This is interesting!